Novel therapies for aggressive b-cell lymphoma

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Foon, Kenneth A ^a   Takeshita, Kenichi ^a   Zinzani, Pier L ^b  

^a CELGENE CORPORATION   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BLINATUMOMAB; CARBOPLATIN; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACETUZUMAB; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; LUCATUMUMAB; MILATUZUMAB; OBINUTUZUMAB; OFATUMUMAB; OXALIPLATIN; PIXANTRONE; PREDNISONE; RITUXIMAB; SB 743921; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 84859754957     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/302570     Document Type: Review

References (232)

1. Armitage J. O., A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma Blood 1997 89 11 3909 3918 (Pubitemid 27220933)
2. Hartmann E. M., Ott G., Rosenwald A., Molecular biology and genetics of lymphomas Hematology/Oncology Clinics of North America 2008 22 5 807 823
3. Morin R. D., Mendez-Lago M., Mungall A. J., Goya R., Mungall K. L., Corbett R. D., Johnson N. A., Severson T. M., Chiu R., Field M., Jackman S., Krzywinski M., Scott D. W., Trinh D. L., Tamura-Wells J., Li S., Firme M. R., Rogic S., Griffith M., Chan S., Yakovenko O., Meyer I. M., Zhao E. Y., Smailus D., Moksa M., Chittaranjan S., Rimsza L., Brooks-Wilson A., Spinelli J. J., Ben-Neriah S., Meissner B., Woolcock B., Boyle M., McDonald H., Tam A., Zhao Y., Delaney A., Zeng T., Tse K., Butterfield Y., Birol I., Holt R., Schein J., Horsman D. E., Moore R., Jones S. J. M., Connors J. M., Hirst M., Gascoyne R. D., Marra M. A., Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 2011 476 7360 298 303
4. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., Kasper L. H., Lerach S., Tang H., Ma J., Rossi D., Chadburn A., Murty V. V., Mullighan C. G., Gaidano G., Rabadan R., Brindle P. K., Dalla-Favera R., Inactivating mutations of acetyltransferase genes in B-cell lymphoma Nature 2011 471 7337 189 195
5. Cerchietti L. C., Hatzi K., Caldas-Lopes E., Yang S. N., Figueroa M. E., Morin R. D., Hirst M., Mendez L., Shaknovich R., Cole P. A., Bhalla K., Gascoyne R. D., Marra M., Chiosis G., Melnick A., BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy Journal of Clinical Investigation 2010 120 12 4569 4582
6. Swerdlow S. H., Campo E., Harris N. L., World Health Organization classification of tumours of haematopoietic and lymphoid tissues. World Health Organization, IARC, Lyon, France, 238, 2008
7. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B., Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte Journal of Clinical Oncology 2005 23 18 4117 4126 (Pubitemid 46211317)
8. Habermann T. M., Weller E. A., Morrison V. A., Gascoyne R. D., Cassileth P. A., Cohn J. B., Dakhil S. R., Woda B., Fisher R. I., Peterson B. A., Horning S. J., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma Journal of Clinical Oncology 2006 24 19 3121 3127 (Pubitemid 46638950)
9. Pfreundschuh M., Trmper L., sterborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P. L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., Lpez-Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncology 2006 7 5 379 391
10. Sehn L. H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., MacPherson N., O'Reilly S., Spinelli J. J., Sutherland J., Wilson K. S., Gascoyne R. D., Connors J. M., Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia Journal of Clinical Oncology 2005 23 22 5027 5033 (Pubitemid 46224009)
11. Rosenwald A., Wright G., Chan W. C., Connors J. M., Campo E., Fisher R. I., Gascoyne R. D., Konrad Muller-Hermelink H., Smeland E. B., Giltnane J. M., Hurt E. M., Zhao H., Averett L., Yang L., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D., Powell J., Duffey P. L., Longo D. L., Greiner T. C., Weisenburger D. D., Sanger W. G., Dave B. J., Lynch J. C., Vose J., Armitage J. O., Montserrat E., Lpez-Guillermo A., Grogan T. M., Miller T. P., Leblanc M., Ott G., Kvaloy S., Delabie J., Holte H., Krajci P., Stokke T., Staudt L. M., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma New England Journal of Medicine 2002 346 25 1937 1947 (Pubitemid 34651353)
12. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R. D., Chan W. C., Zhao T., Haioun C., Greiner T. C., Weisenburger D. D., Lynch J. C., Vose J., Armitage J. O., Smeland E. B., Kvaloy S., Holte H., Delabie J., Campo E., Montserrat E., Lopez-Guillermo A., Ott G., Muller H. K., Connors J. M., Braziel R., Grogan T. M., Fisher R. I., Miller T. P., LeBlanc M., Chiorazzi M., Zhao H., Yang L., Powell J., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D., Staudt L. M., Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma Journal of Experimental Medicine 2003 198 6 851 862 (Pubitemid 37152922)
13. Savage K. J., Monti S., Kutok J. L., Cattoretti G., Neuberg D., De Leval L., Kurtin P., Dal Cin P., Ladd C., Feuerhake F., Aguiar R. C. T., Li S., Salles G., Berger F., Jing W., Pinkus G. S., Habermann T., Dalla-Favera R., Harris N. L., Aster J. C., Golub T. R., Shipp M. A., The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma Blood 2003 102 12 3871 3879 (Pubitemid 37486965)
14. Wright G., Tan B., Rosenwald A., Hurt E. H., Wiestner A., Staudt L. M., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma Proceedings of the National Academy of Sciences of the United States of America 2003 100 17 9991 9996 (Pubitemid 37087056)
15. Alizadeh A. A., Eisen M. B., Davis R. E., Ma C. L., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Mar G. E., Moore T., Hudson J., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Levy R., Wilson W., Grever M. R., Byrd J. C., Botstein D., Brown P. O., Staudt L. M., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 2000 403 6769 503 511 (Pubitemid 30082188)
16. Dave S. S., Fu K., Wright G. W., Lam L. T., Kluin P., Boerma E. J., Greiner T. C., Weisenburger D. D., Rosenwald A., Ott G., Mller-Hermelink H. K., Gascoyne R. D., Delabie J., Rimsza L. M., Braziel R. M., Grogan T. M., Campo E., Jaffe E. S., Dave B. J., Sanger W., Bast M., Vose J. M., Armitage J. O., Connors J. M., Smeland E. B., Kvaloy S., Holte H., Fisher R. I., Miller T. P., Montserrat E., Wilson W. H., Bahl M., Zhao H., Yang L., Powell J., Simon R., Chan W. C., Staudt L. M., Molecular diagnosis of Burkitt's lymphoma New England Journal of Medicine 2006 354 23 2431 2442 (Pubitemid 43855046)
17. Xiao C., Srinivasan L., Calado D. P., Patterson H. C., Zhang B., Wang J., Henderson J. M., Kutok J. L., Rajewsky K., Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes Nature Immunology 2008 9 4 405 414 (Pubitemid 351405110)
18. Young K. H., Leroy K., Mller M. B., Colleoni G. W. B., Snchez-Beato M., Kerbauy F. R., Haioun C., Eickhoff J. C., Young A. H., Gaulard P., Piris M. A., Oberley T. D., Rehrauer W. M., Kahl B. S., Malter J. S., Campo E., Delabie J., Gascoyne R. D., Rosenwald A., Rimsza L., Huang J., Braziel R. M., Jaffe E. S., Wilson W. H., Staudt L. M., Vose J. M., Chan W. C., Weisenburger D. D., Greiner T. C., Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study Blood 2008 112 8 3088 3098
19. Lenz G., Wright G. W., Emre N. C., Kohlhammer H., Dave S. S., Davis R. E., Carty S., Lam L. T., Shaffer A. L., Xiao W., Powell J., Rosenwald A., Ott G., Muller-Hermelink H. K., Gascoyne R. D., Connors J. M., Campo E., Jaffe E. S., Delabie J., Smeland E. B., Rimsza L. M., Fisher R. I., Weisenburger D. D., Chan W. C., Staudt L. M., Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13520 13525
20. Weniger M. A., Melzner I., Menz C. K., Wegener S., Bucur A. J., Dorsch K., Mattfeldt T., Barth T. F. E., Mller P., Mutations of the tumor suppressor gene SOCS -1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation Oncogene 2006 25 18 2679 2684
21. Mestre C., Rubio-Moscardo F., Rosenwald A., Climent J., Dyer M. J. S., Staudt L., Pinkel D., Siebert R., Martinez-Climent J. A., Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays Leukemia 2005 19 6 1082 1084 (Pubitemid 40862024)
22. Melzner I., Bucur A. J., Brderlein S., Dorsch K., Hasel C., Barth T. F. E., Leithuser F., Mller P., Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line Blood 2005 105 6 2535 2542 (Pubitemid 40387056)
23. Kramer M. H., Hermans J., Wijburg E., Philippo K., Geelen E., Van Krieken J. H. J. M., De Jong D., Maartense E., Schuuring E., Kluin P. M., Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma Blood 1998 92 9 3152 3162 (Pubitemid 28492322)
24. NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphoma, 2004, http://www.nccn.org/professionals/physiciangls/pdf/nhl.pdf
25. Yang W. I., Zukerberg L. R., Motokura T., Arnold A., Harris N. L., Cyclin D1 (Bcl -1, PRAD 1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia American Journal of Pathology 1994 145 1 86 96 (Pubitemid 24217487)
26. Jares P., Campo E., Advances in the understanding of mantle cell lymphoma British Journal of Haematology 2008 142 2 149 165 (Pubitemid 351994053)
27. Pinyol M., Hernandez L., Cazorla M., Balbn M., Jares P., Fernandez P. L., Montserrat E., Cardesa A., Lopez-Otn C., Campo E., Deletions and loss of expression of P16INK4a and P21Waf1 genes are associated with aggressive variants of mantle cell lymphomas Blood 1997 89 1 272 280 (Pubitemid 26428202)
28. Greiner T. C., Moynihan M. J., Chan W. C., Lytle D. M., Pedersen A., Anderson J. R., Weisenburger D. D., p53 Mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis Blood 1996 87 10 4302 4310 (Pubitemid 26152272)
29. Greiner T. C., Dasgupta C., Ho V. V., Weisenburger D. D., Smith L. M., Lynch J. C., Vose J. M., Fu K., Armitage J. O., Braziel R. M., Campo E., Delabie J., Gascoyne R. D., Jaffe E. S., Muller-Hermelink H. K., Ott G., Rosenwald A., Staudt L. M., Im M. Y., Karaman M. W., Pike B. L., Chan W. C., Hacia J. G., Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma Proceedings of the National Academy of Sciences of the United States of America 2006 103 7 2352 2357 (Pubitemid 43271673)
30. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C., Belhadj K., Bordessoule D., Fermé C., Tilly H., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 2010 116 12 2040 2045
31. Cunningham D., Smith P., Mouncey P., R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma Journal of Clinical Oncology 2011 29 15s, abstract 8000
32. Thieblemont C., Briere J., Mounier N., Prognostic impact of germinal center (GC)/ activated B-Cell (ABC) classification analysed by immunochemistry, FISH analysis and GEP, in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL). The Bio-CORAL Study Blood 2010 116, abstract 993
33. Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D. C., Trneny M., Bosly A., Ketterer N., Shpilberg O., Hagberg H., Ma D., Brire J., Moskowitz C. H., Schmitz N., Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era Journal of Clinical Oncology 2010 28 27 4184 4190
34. Cortelazzo A., Ponzoni M., Ferreri A. J. M., Dreyling M., Mantle cell lymphoma. Critical Reviews in Oncology/Hematology. In press
35. Rummel M. J., Al-Batran S. E., Kim S. Z., Welslau M., Hecker R., Kofahl-Krause D., Josten K. M., Drk H., Rost A., Neise M., Von Grnhagen U., Chow K. U., Hansmann M. L., Hoelzer D., Mitrou P. S., Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma Journal of Clinical Oncology 2005 23 15 3383 3389
36. Robinson K. S., Williams M. E., Van Der Jagt R. H., Cohen P., Herst J. A., Tulpule A., Schwartzberg L. S., Lemieux B., Cheson B. D., Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma Journal of Clinical Oncology 2008 26 27 4473 4479
37. Ohmachi K., Ando K., Ogura M., Uchida T., Itoh K., Kubota N., Ishizawa K., Yamamoto J., Watanabe T., Uike N., Choi I., Terui Y., Usuki K., Nagai H., Uoshima N., Tobinai K., Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma Cancer Science 2010 101 9 2059 2064
38. Ogura M., Ando K., Taniwaki M., Watanabe T., Uchida T., Ohmachi K., Matsumoto Y., Tobinai K., Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma Cancer Science 2011 102 9 1687 1692
39. Ogura M., Uchida T., Ando K., Bendamustine is highly effective for relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL): final results of a Japanese multicenter phase II study Blood 2009 114, abstract 3694
40. Vacirca J., Tabbara I., Acs P., Shumaker G., Bendamustine + rituximab as treatment for elderly patients with relapsed or refractory diffuse large B-Cell lymphoma Blood 2010 116, abstract 2806
41. Rummel M. J., Kaiser U., Balser C., Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomasfinal results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany Blood 2010 116, abstract 856
42. Rummel M. J., Niederle N., Maschmeyer G., Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) Blood 2009 114, abstract 405
43. Rigacci L., Puccini B., Orciuolo E., Safety and efficacy of bendamustine with or without rituximab for the treatment of heavily pretreated CLL and lymphoma patients. A multicenter retrospective study Blood 2009 114, abstract 1662
44. Sanchez-Gonzalez B., Penalver F. J., Guillen H., Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia: Spanish Registry Blood 2009 114, abstract 3698
45. Lpez A., Gutiérrez A., Palacios A., Blancas I., Navarrete M., Morey M., Perell A., Alarcn J., Martnez J., Rodrguez J., GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study European Journal of Haematology 2008 80 2 127 132
46. Gironella M., Lpez A., Pau A., Rituximab plus gemcitabine and oxaliplatin as salvage therapy in patients with relapsed/refractory mantle-cell lymphoma Blood 2010 116, abstract 2825
47. El Gnaoui T., Dupuis J., Belhadj K., Jais J. P., Rahmouni A., Copie-Bergman C., Gaillard I., Diviné M., Tabah-Fisch I., Reyes F., Haioun C., Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy Annals of Oncology 2007 18 8 1363 1368 (Pubitemid 47305011)
48. Corazzelli G., Capobianco G., Arcamone M., Ballerini P. F., Iannitto E., Russo F., Frigeri F., Becchimanzi C., Marcacci G., De Chiara A., Pinto A., Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma Cancer Chemotherapy and Pharmacology 2009 64 5 907 916
49. Pettengell R., Zinzani P. L., Narayanan G., Phase 3 trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin lymphoma (EXTEND): end of study results Blood 2010 116, abstract 2833
50. Rodriguez M. A., Pytlik R., Kozak T., Chhanabhai M., Gascoyne R., Lu B., Winter J. N., Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study Cancer 2009 115 15 3475 3482
51. Bongero D. C., Paoluzzi L., Marchi E., The novel kinesin spindle protein inhibitor SB-743921 exhibits marked activity in in vivo and in vitro in models of aggressive diffuse large B-cell lymphoma Blood 2010 116, abstract 118
52. O'Connor O. A., Gerecitano J., Van Deventer H., A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed Q14D without and with prophylactic G-CSF in non-Hodgkin (NHL) or Hodgkin lymphoma (HL) Blood 2009 114, abstract 1673
53. Abramson J. S., Takvorian T., Jacobsen E. D., A phase I dose-escalation trial of oral clofarabine for relapsed/refractory non-hodgkin lymphoma Blood 2010 116, abstract 1775
54. Czuczman M. S., Gregory S. A., The future of CD20 monoclonal antibody therapy in B-cell malignancies Leukemia and Lymphoma 2010 51 6 983 994
55. Goldenberg D. M., Rossi E. A., Stein R., Cardillo T. M., Czuczman M. S., Francisco J. H. I., Hansen H. J., Chang C. H., Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody Blood 2009 113 5 1062 1070
56. Morschhauser F., Leonard J. P., Fayad L., Coiffier B., Petillon M. O., Coleman M., Schuster S. J., Dyer M. J. S., Horne H., Teoh N., Wegener W. A., Goldenberg D. M., Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma. Phase I/II results Journal of Clinical Oncology 2009 27 20 3346 3353
57. Christian B., Alinari L., Earl C. T., A phase I study of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma Blood 2010 116, abstract 2788
58. Prescribing information ofatuzumab, GlaxoSmithKline Research, Triangle Park, NC, USA, 2011
59. Barth M., Hernandez-Ilizaliturri F. J., Mavis C., Ofatumumab, a fully human monoclonal antibody targeting CD20, demonstrates activity against and potentiates the anti-tumor activity of chemotherapy agents in rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell non-Hodgkin lymphoma (NHL) Blood 2010 116, abstract 3917
60. Coiffier B., Bosly A., Wu K. L., Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter phase II study Blood 2010 116, abstract 3955
61. Niederfellner G. J., Lammens A., Schwaiger M., Crystal structure analysis reveals that the novel type II anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way Blood 2009 114, abstract 3726
62. Heinrich D. A., Klein C., Decheva K., Anti-CD20 antibody GA101 shows higher cytotoxicity but is competitively displaced by rituximab in mantle cell lymphoma Blood 2009 114, abstract 2704
63. Herter S., Waldhauer I., Otz T., Superior efficacy of the novel type II, glycoengineered CD20 antibody GA101 vs. the type I CD20 antibodies rituximab and ofatumumab Blood 2010 116, abstract 3925
64. Salles G., Morschhauser F., Lamy T., Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20 + non-Hodgkin lymphoma (NHL) Blood 2009 114, abstract 1704
65. Sehn L. H., Assouline S. E., Stewart D. A., A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed/refractory CD20 + malignant disease Blood 2009 114, abstract 934
66. Cartron G., Thieblemont C., Solal-Celigny P., Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patientsfirst results from a phase II study in patients with relapsed/refractory DLBCL and MCL Blood 2010 116, abstract 2878
67. Herting F., Bader S., Umana P., Klein C., Enhanced activity of GA101, a novel type II, glycoengineered CD20 antibody, in combination with bendamustine or fludarabine, and with the Bcl-2 family inhibitors ABT-737 or ABT-263 Blood 2010 116, abstract 3915
68. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., Juan T., Talvenheimo J., Montestruque S., Sun J., Elliott G., Thomas J., Ferbas J., Kern B., Briddell R., Leonard J. P., Cesano A., Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research 2003 9 10 3982S 3990S (Pubitemid 37169205)
69. Strauss S. J., Morschhauser F., Rech J., Repp R., Solal-Celigny P., Zinzani P. L., Engert A., Coiffier B., Hoelzer D. F., Wegener W. A., Teoh N. K. W., Goldenberg D. M., Lister T. A., Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma Journal of Clinical Oncology 2006 24 24 3880 3886 (Pubitemid 46630735)
70. Micallef I. N., Maurer M. J., Nikcevich D. A., Final results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Journal of Clinical Oncology 2009 27 15s, abstract 8508
71. Micallef I. N., Maurer M. J., Witzig T. E., PET scan results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Blood 2009 114, abstract 137
72. Stein R., Chen S., Hernandez-Ilizaliturri F. J., Czuczman M. S., Goldenberg D. M., Milatuzumab improves efficacy of current treatments for B-cell malignancies Blood 2010 116, abstract 2837
73. Alinari L., Christian B., Yu B., Co-treatment with milatuzumab (anti-CD74 mAb) and rituximab (anti-CD20 mAb) results in the induction of mantle cell lymphoma cell death that is dependent on actin polymerization and inhibition of NF-Kb Blood 2009 114, abstract 1694
74. Freedman A. S., Kuruvilla J., Assouline S. E., Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592) Blood 2010 116, abstract 284
75. Law C. L., Gordon K. A., Collier J., Klussman K., McEarchern J. A., Cerveny C. G., Mixan B. J., Lee W. P., Lin Z., Valdez P., Wahl A. F., Grewal I. S., Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40 Cancer Research 2005 65 18 8331 8338 (Pubitemid 41330598)
76. Lewis T. S., McCormick R. S., Emmerton K., Lau J. T., Yu S. -F., McEarchern J. A., Grewal I. S., Law C. -L., Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma Clinical Cancer Research 2011 17 14 4672 4681
77. Forero-Torres A., Bartlett N. L., Nasta S. D., A phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: multiple responses observed in patients with relapsed diffuse large B-cell lymphoma Blood 2009 114, abstract 586
78. Hayden-Ledbetter M. S., Cerveny C. G., Espling E., Brady W. A., Grosmaire L. S., Tan P., Bader R., Slater S., Nilsson C. A., Barone D. S., Simon A., Bradley C., Thompson P. A., Wahl A. F., Ledbetter J. A., CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells Clinical Cancer Research 2009 15 8 2739 2746
79. Zhao X., Ybarra S., Durkin L., CD37 is a potential therapeutic target for B-cell non-Hodgkin lymphoma Blood 2010 116, abstract 3098
80. Algate P. A., Wiens J., Nilsson C., TRU-016, an anti-CD37 SMIP biologic, in combination with other therapeutic drugs in models of Non-Hodgkin's Lymphoma Blood 2010 116, abstract 3931
81. Baum P. R., Cerveny C., Gordon B., Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma Journal of Clinical Oncology 2009 27 15s, abstract 8571
82. Newell L., Tuscano J., Ma Y., Martin S., O'Donnell R., The bispecific anti-CD20/CD22 antibody (Bs20x22) has more lymphomacidal activity than the parent antibodies both alone or in combination Blood 2010 116, abstract 425
83. Nordstrom D. L., Rossi E. A., Goldenberg D. M., Chang C.-H., First bispecific antibody immunocytokine (anti-CD20/HLA-DR-interferon-a2b) is highly toxic for human lymphoma cells in vitro Blood 2009 114, abstract 1695
84. Baeuerle P. A., Reinhardt C., Bispecific T-cell engaging antibodies for cancer therapy Cancer Research 2009 69 12 4941 4944
85. Viardot A., Goebeler M., Scheele J. S., Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 g/m 2 /d is tolerable and highly effective Blood 2010 116, abstract 2880
86. Gupta P., Stein R., Cardillo T. M., Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways Blood 2009 114, abstract 3738
87. Chao M. P., Alizadeh A. A., Tang C. Z., Therapeutic antibody targeting of CD47 synergizes with rituximab to completely eradicate human B-cell lymphoma xenografts Blood 2009 114, abstract 2716
88. Houot R., Goldstein M. J., Kohrt H. E., Therapeutic potential of anti-CD137 antibody in lymphoma Blood 2009 114, abstract 722
89. Awan F., Lapalombella R., Trotta R., CD19 targeting of lymphoid malignancies by novel Fc-domain engineered monoclonal antibody Blood 2009 114, abstract 3725
90. Rohrer T., Antibody drug conjugates: potent weapons for the oncology arsenal Chemistry Today 2009 27 5 56 60
91. Zein N., Sinha A. M., McGahren W. J., Ellestad G. A., Calicheamin 1(I): an antitumor antibiotic that cleaves double-stranded DNA site specifically Science 1988 240 4856 1198 1201
92. Fayad L., Patel H., Verhoef G., Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase I study Blood 2006 108, abstract 2711
93. Fayad L., Patel H., Verhoef G., Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study Blood 2008 112, abstract 266
94. Wagner-Johnston N., Goy A., Feldman T., Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab in relapsed DLBCL patients followed by stem cell transplantation: preliminary safety and efficacy Blood 2010 116, abstract 2883
95. Hatake K., Ogura M., Ando K., Phase 1 study of anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) plus rituximab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma Blood 2010 116, abstract 2872
96. Morschhauser F., Kraeber-Bodéré F., Wegener W. A., Harousseau J. L., Petillon M. O., Huglo D., Trmper L. H., Meller J., Pfreundschuh M., Kirsch C. M., Naumann R., Kropp J., Horne H., Teoh N., Le Gouill S., Bodet-Milin C., Chatal J. F., Goldenberg D. M., High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma Journal of Clinical Oncology 2010 28 23 3709 3716
97. Kraeber-Bodéré F., Maisonneuve H., Lamy T., Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients, Blood 2010 116, abstract 2875
98. Goldenberg D. M., Govindan S., Cardillo T. M., Sharkey R. M., Epratuzumab (humanized anti-CD22 mAb) conjugated with SN-38, a new antibody-drug conjugate (ADC) for the treatment of hematologic tumors: preclinical studies alone and in combination with veltuzumab, a humanized anti-CD20 mAb Blood 2010 116, abstract 3941
99. Luptakova K., Kim M., Ely P., 90 Y-Ibritumomab tiuxetan followed by rituximab is a safe treatment option for relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma Blood 2010 116, abstract 2866
100. Zinzani P. L., Tani M., Fanti S., Stefoni V., Musuraca G., Vitolo U., Perrotti A., Fina M., Derenzini E., Baccarani M., A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma Cancer 2008 112 4 856 862 (Pubitemid 351246571)
101. Smith M. R., Zhang L., Gordon L. I., Phase II study of R-CHOP followed by 90 Y-Ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group study E1499 Blood 2007 110, abstract 389
102. Friedberg J. W., Unger J. M., Burack W. R., R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group protocol S0433 Blood 2010 116, abstract 590
103. Fromm J. R., McEarchern J. A., Kennedy D., Anju T., Shustov A. R., Gopal A. K., Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab vedotin (SGN-35): a novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin lymphoma Blood 2010 116, abstract 1789
104. Fanale M., Bartlett N. L., Forero-Torres A., The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study Blood 2009 114, abstract 2731
105. Rossi E. A., Chan E., Gupta P., Goldenberg D. M., Chang C.-H., A novel ribonuclease-based immunotoxin comprising quadruple ranpirnase (Rap) site-specifically conjugated to an anti-CD22 IgG showing potent anti-lymphoma activity Blood 2009 114, abstract 3721
106. Kochenderfer J. N., Dudley M. E., Stetler-Stevenson M., A phase I clinical trial of treatment of B-cell malignancies with autologous anti-CD19-CAR-transduced T cells Blood 2010 116, abstract 2865
107. Grille S., Moreno M., Brugnini A., Chabalgoity J. A., Lens D., A therapeutic vaccine using activated tumor cells by Salmonella infection and interleukin-2 induces antitumor immunity in B-cell lymphoma Blood 2010 116, abstract 2841
108. Hamblin A. D., King B. C. R., French R. R., Non-cognate cytotoxic T cells can be retargeted against CD20 positive tumour cells using [Fab' x MHC Class I/Peptide] conjugates Blood 2010 116, abstract 2838
109. Chanan-Khan A. A., Cheson B. D., Lenalidomide for the treatment of B-cell malignancies Journal of Clinical Oncology 2008 26 9 1544 1552
110. Kaufmann H., Raderer M., Whrer S., Pspk A., Bankier A., Zielinski C., Chott A., Drach J., Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood 2004 104 8 2269 2271 (Pubitemid 39331822)
111. Harel S., Bachy E., Haioun C., Efficacy and safety of thalidomide in mantle cell lymphoma: results of the French ATU Program Blood 2010 116, abstract 1794
112. Wiernik P. H., Lossos I. S., Tuscano J. M., Justice G., Vose J. M., Cole C. E., Lam W., McBride K., Wride K., Pietronigro D., Takeshita K., Ervin-Haynes A., Zeldis J. B., Habermann T. M., Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma Journal of Clinical Oncology 2008 26 30 4952 4957
113. Habermann T. M., Lossos I. S., Justice G., Vose J. M., Wiernik P. H.,
114. Witzig T. E., Vose J. M., Zinzani P. L., Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003) Blood 2009 114, abstract 1676
115. Vose J. M., Habermann T., Czuczman M. S., Single-agent lenalidomide for patients with relapsed/refractory aggressive non-Hodgkin's lymphoma who had received prior stem cell transplant Blood 2009 114, abstract 2699
116. Gaidarova S., Corral L. G., Glezer E., Schafer P. H., Lopez-Girona A., Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing Blood 2009 114, abstract 1687
117. Gaidarova S., Mendy D., Heise C., Lenalidomide induces capping of CD20 and cytoskeleton proteins to enhance rituximab immune recognition of malignant B-cells Blood 2010 116, abstract 2845
118. Wang L., Fayad L., Hagemeister F. B., Phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma Blood 2009 114, abstract 2719
119. Zaja F., De Luca S., Vitolo U., Salvage treatment with lenalidomide and dexamethasone in patients with relapsed refractory mantle cell lymphoma: clinical results and modifications of angiogenic biomarkers Blood 2010 116, abstract 966
120. Ahmadi T., Chong E. A., Gordon A., Phase II trial of lenalidomidedexamethasonerituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab Blood 2010 116, abstract 3962
121. Nowakowski G. S., LaPlant B., Habermann T., A phase I/II trial of lenalidomide and RCHOP (R2CHOP) in patients with newly diagnosed diffuse large B-cell (DLBCL) and follicular grade 3 lymphoma Blood 2009 114, abstract 1669
122. Tilly H., Morschhauser F., Salles G. A., A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas Journal of Clinical Oncology 2010 28 15s, abstract TPS297
123. Vitolo U., Chiappella A., Carella A. M., Prospective, multicenter phase I-II pilot trial to evaluate efficacy and safety of lenalidomide plus rituximab-CHOP21 (LR-CHOP21) for elderly patients with untreated diffuse large B-cell lymphoma (DLBCL): interim analysis of the Intergruppo Italiano Linfomi (IIL) REAL07 study Blood 2010 116, abstract 2871
124. Prescribing information bortezomib, Millennium Pharmaceuticals Inc., Cambridge, Mass, USA, 2010
125. Ruan J., Martin P., Furman R. R., CHOP-R + bortezomib as initial therapy for mantle cell lymphoma (MCL) Blood 2009 114, abstract 2682
126. Friedberg J. W., Vose J. M., Kelly J. L., Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial Blood 2009 114, abstract 924
127. Kim J. E., Lee D. H., Lee S. I., Interim report of phase II study of bortezomib plus CHOP every 2 weeks in patients with disseminated stage diffuse large B-cell lymphoma Blood 2009 114, abstract 2688
128. Dunleavy K., Pittaluga S., Czuczman M. S., Dave S. S., Wright G., Grant N., Shovlin M., Jaffe E. S., Janik J. E., Staudt L. M., Wilson W. H., Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 2009 113 24 6069 6076
129. Doner K., Flinn I. W., Ulrich B. K., Rapid prospective identification of non-germinal center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) patients for targeted trials: early results from PYRAMID, a phase 2 randomized study of R-CHOP bortezomib in newly diagnosed non-GCB DLBCL Blood 2010 116, abstract 1792
130. Chiapella A., Pregno P., Zinzani P. L., Weekly infusion of bortezomib in combination with rituximab in relapsed/refractory indolent non-follicular and mantle cell lymphoma is safe and effective: two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi (IIL) Blood 2010 116, abstract 3965
131. Gressin R., Houot R., Uribe M. O., Final results of the RiPAD+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma. A phase II prospective study of the GOELAMS group Blood 2010 116, abstract 2791
132. Gerecitano J., Portlock C. S., Hamlin P. A. Jr., Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas Blood 2009 114, abstract 3708
133. Younes A., Kirschbaum M., Sokol L., Safety and tolerability of conatumumab in combination with bortezomib or vorinostat in patients with relapsed or refractory lymphoma Blood 2009 114, abstract 1708
134. Kirschbaum M., Delioukina M., Popplewell L., Phase I study of bortezomib in combination with gemcitabine in relapsed/refractory intermediate grade B-cell and mantle cell non-Hodgkin's lymphoma Blood 2009 114, abstract 1682
135. Roy R., Evens A. M., Patton D. P., Bortezomib may be safely combined with Y-90 ibritumomab tiuxetan in patients with relapsed/refractory follicular or transformed non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation Blood 2010 116, abstract 1749
136. Deshpande D. S., Lechowicz M. J., Sinha R., The combination of romidepsin and bortezomib results in synergistic induction of apoptosis in human B-lymphoma cell lines Blood 2009 114, abstract 1689
137. Jia L., Gopinathan G., Sukumar J. T., Gribben J. G., Potentiation of bortezomib-induced killing of lymphoma cells by inhibition of autophagy and prevention of I- B degradation Blood 2010 116, abstract 116
138. Tabe Y., Jin L., Kojima K., MDM2 antagonist nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma Blood 2010 116, abstract 3920
139. Hernandez-Ilizaliturri F., Tsio P.-C., Campagna R., Obatoclax and bortezomib therapy results in disruption of the p53-mediated apoptosis/autophagy pathway and is associated with potent synergistic anti-tumor activity against rituximab-chemotherapy-sensitive and -resistant B-cell lymphoma Blood 2009 114, abstract 288
140. Spencer A., Millward M., Mainwaring P., Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 Blood 2009 114, abstract 2693
141. Donelan J., Bannerman B., Bano K., Antitumor activity of MLN9708, a second-generation proteasome inhibitor, in preclinical models of lymphoma Blood 2009 114, abstract 3724
142. Kupperman E., Lee E., Cao Y., In-vitro and in-vivo evaluation of the orally active proteasome inhibitor MLN9708 in hematological models of human cancer Blood 2009 114, abstract 2709
143. Dasmahapatra G., Lembersky D., Kramer L., The novel proteasome inhibitor carfilzomib interacts synergistically with HDAC inhibitors in ABC- and GC-DLBCL cells both in vitro and in vivo through mechanisms involving JNK activation, NF- B inactivation, and DNA damage Blood 2009 114, abstract 1688
144. Hay N., The Akt-mTOR tango and its relevance to cancer Cancer Cell 2005 8 3 179 183 (Pubitemid 41317589)
145. Hay N., Sonenberg N., Upstream and downstream of mTOR Genes and Development 2004 18 16 1926 1945 (Pubitemid 39071573)
146. Prescribing information everolimus, Novartis Pharmaceuticals Corporation, NJ, USA, 2011
147. Prescribing information temsirolimus, Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA, 2011
148. Witzig T. E., Reeder C. B., LaPlant B. R., A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Leukemia 2011 25 2 341 347
149. Renner C., Zinzani P. L., Gressin R., A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Blood 2010 116, abstract 2803
150. O'Connor O. A., Popplewell L., Winter J. N., PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib Blood 2010 116, abstract 3963
151. Ogura M., Uchida T., Maruyama D., Phase I and pharmacokinetic (PK) study of everolimus (RAD001) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) Blood 2009 114, abstract 1712
152. Younes A., Copeland A., Fanale M. A., Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma Blood 2010 116, abstract 3964
153. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., Laurell A., Offner F., Strahs A., Berkenblit A., Hanushevsky O., Clancy J., Hewes B., Moore L., Coiffier B., Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma Journal of Clinical Oncology 2009 27 23 3822 3829
154. Ansell S. M., Tang H., Kurtin P. J., Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study Lancet Oncology 2011 12 4 361 368
155. Smith S. M., van Besien K., Karrison T., Dancey J., McLaughlin P., Younes A., Smith S., Stiff P., Lester E., Modi S., Doyle L. A., Vokes E. E., Pro B., Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium Journal of Clinical Oncology 2010 28 31 4740 4746
156. Lannutti B. J., Meadows S., Kashishian A., CAL-101, an oral p110 selective phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of B cell malignancies inhibits PI3K signaling, cellular viability and protective signals of the microenvironment Blood 2009 114, abstract 286
157. Webb H. K., Chen H., Yu A. S., Clinical pharmacokinetics of CAL-101, a p110o isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies Blood 2010 116, abstract 1774
158. Kahl B., Byrd J. C., Flinn I. W., Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, in patients with relapsed or refractory non-Hodgkin lymphoma Blood 2010 116, abstract 1777
159. Flinn I. W., Byrd J. C., Furman R. R., Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110 isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies Blood 2009 114, abstract 922
160. Flinn I. W., Schreeder M. T., Wagner-Johnston N., A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies Blood 2010 116, abstract 2832
161. Garlich J. R., Becker M. D., Shelton C. F., Phase I study of novel prodrug dual PI3K/mTOR inhibitor SF1126 in B-cell malignancies Blood 2010 116, abstract 1783
162. Huye L. E., Savoldo B., Dotti G., Wilson M. H., Rooney C. M., Combining mTor inhibitors with rapa-resistant T cells: a two-pronged approach to tumor elimination Blood 2010 116, abstract 2853
163. Nordgren T. M., Hegde G., Munger C., Vose J. M., Joshi S., Targeting the PI3K/AKT/survivin pathway with ritonavir in therapy-resistant mantle cell lymphoma Blood 2010 116, abstract 2855
164. Gupta M., Hendrickson A. W., Han J. J., Dual inhibition of mTORC1/mTORC2 induces apoptosis of mantle cell lymphoma by preventing rictor mediated AKTS473 phosphorylation by potentiating AKT2-PHLPP1 association Blood 2010 116, abstract 772
165. Alinari L., Liu Q., Chen C.-S., FTY720 demonstrates promising in-vitro and in-vivo pre-clinical activity by down-modulation of cyclin D1 and pakt in mantle cell lymphoma Blood 2009 114, abstract 3728
166. Gisselbrecht C., Mounier N., Novel agents for diffuse large B-cell lymphoma ASCO Educational Book 2011 2011 321 325
167. Budde L. E., Shustov A., Pagel J. M., Pulse high-dose vorinostat can be delivered with rituximab, ifosphamide, carboplatin, and etoposide in patients with relapsed lymphoma: final results of a phase I trial Blood 2010 116, abstract 2790
168. Lansigan F., Seropian S., Cooper D. L., Potter V., Sowers N., Foss F. M., A phase 1 trial of vorinostat and pegylated liposomal doxorubicin in relapsed or refractory lymphoma Blood 2010 116, abstract 2816
169. Kretzner L., Scuto A., Kowolik C., Combination therapy with the histone deacetylase inhibitor vorinostat plus the novel aurora kinase A inhibitor MK-5108 leads to enhanced lymphoma cell death due to acetylation of p53 and repression of c-Myc, hTERT, and miRNA levels Blood 2009 114, abstract 1690
170. Siegel D., Munster P. N., Rubin E., The combined safety and tolerability profile of vorinostat-based therapy for solid or hematologic malignancies Blood 2009 114, abstract 1710
171. Cotto M., Cabanillas F., Garcia-Manero G., Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease Journal of Clinical Oncology 2011 29 15s, abstract 8056
172. Blum K. A., Liu Z., Lucas D. M., Chen P., Xie Z., Baiocchi R., Benson D. M., Devine S. M., Jones J., Andritsos L., Flynn J., Plass C., Marcucci G., Chan K. K., Grever M. R., Byrd J. C., Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation British Journal of Haematology 2010 150 2 189 195
173. Younes A., Ong T.-C., Ribrag V., Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant Blood 2009 114, abstract 923
174. Kalac M., Kitagawa Y., Venkatraman S. E., Tycko B., O'Connor O. A., Histone deacetylase inhibitors synergistically enhance the cytotoxic effect of hypomethylating agents in models of diffuse large B-cell lymphoma Blood 2009 114, abstract 3720
175. Zain J. M., Foss F. M., de Bono J. S., Interim results of a phase 1 trial of an oral histone deacetylase inhibitor belinostat in patients with lymphoid malignancies Blood 2010 116, abstract 1787
176. Evens A. M., Ai W., Balasubramanian S., Phase I analysis of the safety and pharmacodynamics of the novel broad spectrum histone deacetylase inhibitor (HDACi) PCI-24781 in relapsed and refractory lymphoma Blood 2009 114, abstract 2726
177. Younes A., Hernandez F., Bociek R. G., ENGAGE-501: phase 2 study investigating the role of epigenetic therapy with Entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL), interim results Blood 2010 116, abstract 3959
178. Ashraf U., Czuczman M. S., Marvis C., Gibbs J., Hernandez-Ilizaliturri F. J., Entinostat (SNDX-275), a novel DAC inhibitor, is highly effective in rituximab-[chemotherapy]-sensitive or rituximab-[chemotherapy]-resistant lymphomas and has synergistic anti-tumor activity when combined with bortezomib Blood 2009 114, abstract 3727
179. Hernandez-Ilizaliturri F., Marvis C., Maraj I., Chisti M. M., Gibbs J., Czuczman M. S., The DAC inhibitor, LBH589, is highly effective in both rituximab-sensitive and rituximab-resistant lymphomas and enhances the anti-tumor activity of bortezomib, other chemotherapy agents, and anti-CD20 monoclonal antibodies Blood 2009 114, abstract 2715
180. Smith J. L., Pate A., Fan S., Histone deacetylase inhibition using LBH589 is effective in lymphoma and results in down-regulation of the NF-KB pathway Blood 2009 114, abstract 3730
181. Reddy N., Hicks D., Jagasia M., Amiri K., SNX 2112, an oral Hsp-90 inhibitor exerts antiproliferative effects in combination with bortezomib and rituximab in rituximab resistant non-Hodgkin's lymphoma Blood 2009 114, abstract 3733
182. Reed J. C., Dysregulation of apoptosis in cancer Journal of Clinical Oncology 1999 17 9 2941 2953 (Pubitemid 29415256)
183. Pro B., Leber B., Smith M., Fayad L., Romaguera J., Hagemeister F., Rodriguez A., McLaughlin P., Samaniego F., Zwiebel J., Lopez A., Kwak L., Younes A., Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma British Journal of Haematology 2008 143 3 355 360
184. Wilson W., O'Connor O. O., Roberts A. W., ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) Journal of Clinical Oncology 2009 27 15s, abstract 8574
185. Kahl B., Roberts A. W., Seymour J. F., Navitoclax (ABT-263) plus rituximab: interim results of a phase 1 study in patients with CD20-positive lymphoid malignancies Blood 2010 116, abstract 3943
186. Touzeau C., Dousset C., Bodet L., Rational for the use of a targeted-therapy using ABT-737 in mantle-cell lymphoma Blood 2010 116, abstract 770
187. Hernandez-Ilizaliturri F. J., Khubchandani S., Olejniczak S. H., Hoskin P., Czuczman M. S., Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL) Journal of Clinical Oncology 2009 27 15s, abstract 8543
188. Kita A., Nakahara T., Yamanaka K., Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma Leukemia Research 2011 35 6 787 792
189. Nakata M., Nakahara T., Kita A., YM155, a novel survivin suppressant, improves the antitumor effect of rituximab and rituximab-containing regimens in diffuse large B cell lymphoma (DLBCL) xenograft mouse models Blood 2009 114, abstract 2718
190. Meraldi P., Honda R., Nigg E. A., Aurora kinases link chromosome segregation and cell division to cancer susceptibility Current Opinion in Genetics and Development 2004 14 1 29 36 (Pubitemid 38167474)
191. Qi W., Cooke L. S., Liu X., Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma Biochemical Pharmacology 2011 81 7 881 890
192. Padmanabhan S., Shea T. C., Vose J. M., Phase I study of an investigational Aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies Blood 2010 116, abstract 2799
193. Wilkinson R. W., Odedra R., Heaton S. P., Wedge S. R., Keen N. J., Crafter C., Foster J. R., Brady M. C., Bigley A., Brown E., Byth K. F., Barrass N. C., Mundt K. E., Foote K. M., Heron N. M., Jung F. H., Mortlock A. A., Boyle F. T., Green S., AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis Clinical Cancer Research 2007 13 12 3682 3688 (Pubitemid 46955132)
194. Mahadevan D., Liu X., Persky D. O., Miller T. P., Squires M. S., Qi W., AT9283, a novel pan-Aurora/JAK-2 kinase inhibitor suppresses tumor growth in aggressive B-cell non-Hodgkin's lymphoma Blood 2010 116, abstract 3930
195. Baiocchi R. A., Flynn J. A., Jones J. M., Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor dinaciclib (SCH 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients Blood 2010 116, abstract 3966
196. Prasad A., Shrivastava A., Reddy R., Gillum A. M., Reddy E. P., Groopman J. E., Synergistic effects of a novel water-soluble small molecule, ON 013105, and rituximab on mantle cell lymphoma in vitro and in vivo Blood 2010 116, abstract 771
197. Rossi R. M., Grose V., Pine P., Fisher R. I., Jordan C. T., Friedberg J. W., Rational combinations including a novel Syk inhibitor, fostamatinib disodium (FosD) in diffuse large B cell lymphoma Blood 2009 114, abstract 283
198. Friedberg J. W., Sharman J., Sweetenham J., Johnston P. B., Vose J. M., LaCasce A., Schaefer-Cutillo J., De Vos S., Sinha R., Leonard J. P., Cripe L. D., Gregory S. A., Sterba M. P., Lowe A. M., Levy R., Shipp M. A., Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010 115 13 2578 2585
199. Hans C. P., Weisenburger D. D., Greiner T. C., Chan W. C., Aoun P., Cochran G. T., Pan Z., Smith L. M., Lynch J. C., Bociek R. G., Bierman P. J., Vose J. M., Armitage J. O., Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma Modern Pathology 2005 18 10 1377 1384 (Pubitemid 41348658)
200. Robertson M. J., Kahl B. S., Vose J. M., De Vos S., Laughlin M., Flynn P. J., Rowland K., Cruz J. C., Goldberg S. L., Musib L., Darstein C., Enas N., Kutok J. L., Aster J. C., Neuberg D., Savage K. J., LaCasce A., Thornton D., Slapak C. A., Shipp M. A., Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma Journal of Clinical Oncology 2007 25 13 1741 1746 (Pubitemid 46797955)
201. Forsyth C. J., Gomez D., Eliadis P., Enzastaurin in patients with non-Hodgkin lymphomas: a multicenter, open-label, screening study Blood 2009 114, abstract 3719
202. William B. M., Hohenstein M., Loberiza F. R. Jr., Phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) Blood 2010 116, abstract 288
203. Honigberg L. A., Smith A. M., Sirisawad M., Verner E., Loury D., Chang B., Li S., Pan Z., Thamm D. H., Miller R. A., Buggy J. J., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proceedings of the National Academy of Sciences of the United States of America 2010 107 29 13075 13080
204. Fowler N., Sharman J. P., Smith S. M., The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study Blood 2010 116, abstract 964
205. Gambacorti-Passerini C. B., Dilda I., Giudici G., Clinical activity of crizotinib in advanced, chemoresistant ALK+ lymphoma patients Blood 2010 116, abstract 2877
206. Bhalla S., Gartenhaus R., Dai B., The novel 2nd generation small molecule MEK inhibitor, AZD-6244, induces cell death in lymphoma cell lines, primary cells, and in a human lymphoma xenograft model Blood 2009 114, abstract 285
207. Younes A., Fanale M. A., McLaughlin P., Copeland A., Zhu J., de Castro Faria S., Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes Blood 2010 116, abstract 2830
208. Pham L. V., Tamayo A. T., Li C., Bornmann W., Priebe W., Ford R. J., Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications Molecular Cancer Therapeutics 2010 9 7 2026 2036
209. Leonard J. P., Link B. K., Emmanouilides C., Gregory S. A., Weisdorf D., Andrey J., Hainsworth J., Sparano J. A., Tsai D. E., Horning S., Krieg A. M., Weiner G. J., Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma Clinical Cancer Research 2007 13 20 6168 6174 (Pubitemid 350075077)
210. Wang D., Precopio M., Reardon M., Antitumor activity of an RNA-based agonist of TLR7 and 8 in preclinical models of hematological malignancies Blood 2010 116, abstract 421
211. Buglio D., Palakurthi S., Byth K. F., Younes A., The Tak-1 inhibitor AZ-Tak1 inhibits XIAP, activates caspase-9, and induces apoptosis in mantle cell lymphoma Blood 2009 114, abstract 1692
212. Timmerman J., Betting D., Yamada R., In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20 + B-cell lymphoma Journal of Clinical Oncology 2009 27 15s, abstract 8529
213. Yamada R. E., Betting D. J., Ahdoot M., Steward K. K., Timmerman J. M., Direct growth inhibition of both mouse and human B cell lymphomas by CpG oligodeoxynucleotides Blood 2010 116, abstract 2854
214. Isaacs J. S., Xu W., Neckers L., Heat shock protein 90 as a molecular target for cancer therapeutics Cancer Cell 2003 3 3 213 217 (Pubitemid 37443877)
215. Jin L., Tabe Y., Kimura S., Zhou Y., Kuroda J., Asou H., Inaba T., Konopleva M., Andreeff M., Miida T., Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma British Journal of Cancer 2011 104 1 91 100
216. Younes A., Copeland A. R., Romaguera J., Clinical and biologic activity of the heat shock protein-90 (HSP-90) inhibitor 17-AAG in patients with relapsed lymphoma Blood 2009 114, abstract 3744
217. Ribatti D., Scavelli C., Roccaro A. M., Crivellato E., Nico B., Vacca A., Hematopoietic cancer and angiogenesis Stem Cells and Development 2004 13 5 484 495 (Pubitemid 39473579)
218. Stopeck A. T., Unger J. M., Rimsza L. M., Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab (R-CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group study S0515 Blood 2010 116, abstract 591
219. Buckstein R., Kuruvilla J., Chua N., Sunitinib in relapsed or refractory diffuse large B cell lymphoma: results of a phase II multi-center study of the NCIC Clinical Trials Group Blood 2009 114, abstract 2729
220. Kuhnowski F., Thieblemont C., Jardin F., A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma Journal of Clinical Oncology 2010 28 15s, abstract 8010
221. Guidetti A., Carlo-Stella C., Devizzi L., Preliminary results of a phase II trial with the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory non-Hodgkin lymphoma (NHL) Blood 2009 114, abstract 1658
222. Carlo-Stella C., Guidetti A., Viviani S., Clinical activity and safety of the combined therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory lymphomas: preliminary results of a phase II trial Blood 2010 116, abstract 2861
223. Kumar S., Porrata L. F., Ansell S. M., Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma Blood 2010 116, abstract 2802
224. Witzig T. E., Hui T., Micallef I. N., A phase II study of the farnesyltransferase inhibitor tipifarnib demonstrates anti-tumor activity in patients with relapsed and refractory lymphomas Blood 2010 116, abstract 287
225. Shah J. J., Harvey R. D., O'Connor O. A., Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and/or refractory multiple myeloma or lymphoma Blood 2010 116, abstract 2801
226. Traore T., Garnsey J. J., Koenig E., Pre-clinical antitumor activity of MLN4924, an inhibitor of NEDD8-activating enzyme (NAE), in a novel primary human DLBCL xenograft model Blood 2009 114, abstract 927
227. Pham L. V., Bryant J., Tamayo A., Metabolic targeted therapy for aggressive B-cell lymphomas: evaluating glucose metabolism and the potential of 187 rhenium- ethylenedicysteine N-Acetylglucosamine (187 Re-ECG) for therapy Blood 2010 116, abstract 117
228. Gu L., Zhu N., Findley H. W., Zhou M., MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2 Leukemia 2008 22 4 730 739 (Pubitemid 351552622)
229. Siders W., Hu Y., Gale M., Treatment with the CXCR4 antagonist AMD3100 enhances antibody mediated killing in disseminated lymphoma models Blood 2009 114, abstract 2717
230. Leroux D., Le Marc' Hadour F., Gressin R., Jacob M. C., Keddari E., Monteil M., Caillot P., Jalbert P., Sotto J. J., Non-Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma? British Journal of Haematology 1991 77 3 346 353
231. Singh A., Evens A. M., Anderson R., All trans retinoic acid nanodisks enhance retinoic acid receptor-mediated apoptosis and cell cycle arrest in mantle cell lymphoma Blood 2009 114, abstract 3722
232. Bhalla S., Gordon L. I., Singh A., PX-478, a novel small molecule inhibitor of hypoxia inducible factor-1 (HIF-1) downregulates HIF and induces cytotoxicity in diffuse large B cell lymphoma cells Blood 2009 114, abstract 2713